Advances in Age-related Macular Degeneration Understanding and Therapy.

US Ophthalmic Rev · 2017 · PMC5683729 · PMID 29142592

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The study showed a trend to reduction in GA progression of 20%, but was not significant. 58 Two phase III trials to investigate the safety and efficacy of monthly or 6-weekly injections of lampalizumab have completed recruiting participants (CHROMA, NCT02247479 and SPECTRI, NCT02247531 ). 59 , 60 Results of the phase III study SPECTRI were recently announced and showed no efficacy.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.